Physician profile
Cale S Li
NPI 1134784762
$2,269.18
in general payments reported to CMS, 2019-2025
17 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $447 · 2024: $1,190 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.18 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $605.32 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $232.81 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $176.80 | 2023-2025 | Otezla, Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $156.12 | 2024-2025 | Opsumit, Uptravi |
| Viiv Healthcare Company | $150.99 | 2025 | Apretude |
| Exact Sciences Corporation | $143.27 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $139.72 | 2024-2025 | |
| Gilead Sciences, INC. | $127.65 | 2023-2024 | Epclusa |
| Novo Nordisk INC | $124.05 | 2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $109.00 | 2024-2025 | Mounjaro, Zepbound |
| Smith+Nephew, INC. | $107.89 | 2023-2024 | Collagenase Santyl, Regranex |
| Xeris Pharmaceuticals, INC. | $69.20 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.28 | 2023-2025 | Jardiance |
| Shield Therapeutics INC | $20.03 | 2025 | |
| Glaxosmithkline, LLC. | $18.34 | 2023 | Trelegy Ellipta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.40 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cale Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.